Sign Out
Emla can potentiate the formation of methaemoglobin in patients who are being treated with certain methaemoglobin-inducing preparations (eg, sulfa preparations).
With high doses of Emla, the risk of additive systemic effects should be taken into account in patients who are given local anaesthetics or preparations that are structurally similar to local anaesthetics eg, tocainide.
Specific interaction studies with lidocaine/prilocaine and class III antiarrhythmic drugs (eg, amiodarone) have not been performed, but caution is advised. (See Precautions.)
Medicinal products that reduce the clearance of lidocaine (eg, cimetidine or β-blockers) may cause potentially toxic plasma levels when lidocaine is given in repeated high doses for prolonged periods of time. Such interactions are not clinically significant in short-term treatment with lidocaine at recommended doses.
